Alertgy
Non-invasive glucose monitoring.
Melbourne, Florida, United States
Alertgy is a healthcare technology company focused on revolutionizing diabetes management through its non-invasive continuous glucose monitoring (NICGM) technology, DeepGluco™. Positioned to disrupt the market, it utilizes a patented RF sensor in a wristband, combined with AI and machine learning, to provide real-time glucose and vital sign data.
How We Help
Problem Statement
Alertgy addresses the significant pain point of invasive or minimally invasive glucose monitoring methods, which often lead to low patient adoption and adherence for millions of diabetics globally.
Core Technology
Alertgy's core technology is its Non-Invasive Continuous Glucose Monitor (NICGM), known as DeepGluco™. This technology utilizes a patented radio frequency (RF) sensor embedded in a wristband, combined with advanced machine learning and artificial intelligence.
Key Differentiators
Alertgy offers a completely non-invasive approach to glucose monitoring, eliminating the need for needles or blood draws. It aims to measure actual blood glucose levels in real-time (up to three times per minute) with minimal lag, unlike some CGMs that measure interstitial fluid. The device also tracks other vital signs like heart rate, blood oxygen level, and body temperature, and integrates AI and machine learning for accurate readings and personalized insights.
Target Customers
Millions of diabetics globally (Type 1, Type 2, and pre-diabetes patients)
Product Stage
Prototype
Company Info
- Business Model
- SaaS
- Founded
- 2016
- Total Funding
- 750,000
- Website
- alertgy.com
Categories
Technologies
Clinical & IP
Clinical Validation
Alertgy's technology requires robust and transparent clinical validation to demonstrate its accuracy and reliability for measuring actual blood glucose levels without interstitial lag. Securing necessary regulatory approvals, such as FDA clearance in the US, is a crucial upcoming step.
IP Protection
Patented technology (radio frequency sensor)
MedStartr Index Score
?What do you think of Alertgy?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.